I was real busy with patients today. We are now do
Post# of 36564
(Total Views: 360)
Posted On: 03/19/2020 9:28:37 PM
I was real busy with patients today. We are now doing a brief assessment for Covid-19 on any patient that isn't in near perfect health. LOL. Turns out healthy people are few and far between.
I am surprised by the reaction by some to today's press release. Generex is using old tech, newly reborn thanks to Covid-19 (probably not politically correct to be thankful for this disease), providing the company a promising revenue source we hadn't been thinking about 2 months ago. We have a deal with China which, as progress is made delivering the vaccine will provide entry into other countries. Just 2-3 licensing deals will result in our value skyrocketing. Build it and they will come.
I am pissed at the market ignoring us with Covid-19. Hard to see the gains some of these companies have made. A few have held up, others have not. We have the misfortune of bad timing. Number one we are on the OTC, still. Those other companies are not. That sucks for us. We know what Generex's plan is to up list. Is it taking a long time? Yep. Is it going to happen? As far as I know everything is still a go. GNBT's S-1 is the key. Shouldn't be far off now. Two, we had just gotten our dividend paid, then the pop comes, traders and recent underwater longs have been getting out since the China deal news. All those new shares in the float had to get swallowed. Our overall timing is awful even though CV is what gave us the opportunity in the first place. An unexpected opportunity.
Read the line I highlighted in CYDY's press release today about injecting Covid-19 patient's with leronlimab.
U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s Leronlimab
Download as PDFMarch 19, 2020 6:00am EDT
A leading academic medical center has administered the test medication, leronlimab, in two of their sickest COVID-19 patients. Neither patient has had any serious adverse reactions to leronlimab since it was administered. We are hopeful leronlimab will provide help to severely ill COVID-19 patients.
VANCOUVER, Washington, March 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that two coronavirus patients were treated with the Company’s investigational new drug, leronlimab. The treatment was administered at a leading medical center in the New York City area under an emergency Investigational New Drug (IND) recently granted by the U.S. Food and Drug Administration (FDA). Leronlimab is intended to serve as a therapy for patients who experience respiratory illness as a result of contracting the Coronavirus Disease 2019 (COVID-19). The treatment of these patients was not under the Company’s proposed randomized controlled Phase 2 clinical trial protocol recently submitted to the FDA.
Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn, added, “Leronlimab binds to the CCR5 receptor inhibiting the migration of macrophages and the release on inflammatory cytokines including TNF and IL-6. This release of cytokines is what is commonly referred to as the 'cytokine storm' and is believed to cause profound damage in the lungs in some patients. In addition, leronlimab can block Regulatory T cells (Tregs), which can inhibit the innate immune response against pathogens, into areas of inflammation. These combined mechanisms of action may reduce the morbidity and mortality in moderate to severe cases of COVID-19, preventing the acute respiratory distress syndrome associated with this highly destructive and potentially fatal disease.”
Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said, “We are very pleased that we have a potential treatment option for patients affected by COVID-19 infection. To be very clear, leronlimab does not kill the novel coronavirus. It acts as a CCR5 antagonist by blocking pro-inflammatory cytokines, which prevents cytokine storm and thus could be useful in treatment of COVID-19. Leronlimab is administered as a once-a-week injection. It has a strong safety profile demonstrated in nine clinical trials with over 800 people and is available for urgent treatment. If results are promising, we have leronlimab available for immediate use and the ability to scale production. We are open and willing to work with government agencies and pharmaceutical partnerships to assist in serving those in dire need of a treatment option for this devastating disease. We appreciate the FDA’s prompt response and are working in full support of the treating medical team.”
My point is, we are not the only one's starving for the world's attention guys. Worse than that CYDY uses the selling of shares and warrants to raise money thus diluting shareholders. They just did it again today, probably the fourth or fifth time they have since I bought in. Once was for less than 30 cents. That is painful to suffer through. Joe has done everything he can do to avoid having us endure that kind of dilution. He could have done it and we could have hundreds of millions shares in the float to work through before we see a positive return.
We have a more than solid leadership team. Even if Joe is a bit unorthodox in his individual communications and posts, you cannot deny he is well liked by many of his peers. They are still here after all this time and more coming on board because of his vision and the future potential. One cannot ignore what TT, Dr Patel and the new NGIO BOD have accomplished in their professional careers. It isn't all on Joe's shoulders. Why are all these folks on board? It isn't because of the current pay.
I think the rest of March and April will be interesting. Come on SEC, let's get Generex's S-1 approved!
Stay well...
I am surprised by the reaction by some to today's press release. Generex is using old tech, newly reborn thanks to Covid-19 (probably not politically correct to be thankful for this disease), providing the company a promising revenue source we hadn't been thinking about 2 months ago. We have a deal with China which, as progress is made delivering the vaccine will provide entry into other countries. Just 2-3 licensing deals will result in our value skyrocketing. Build it and they will come.
I am pissed at the market ignoring us with Covid-19. Hard to see the gains some of these companies have made. A few have held up, others have not. We have the misfortune of bad timing. Number one we are on the OTC, still. Those other companies are not. That sucks for us. We know what Generex's plan is to up list. Is it taking a long time? Yep. Is it going to happen? As far as I know everything is still a go. GNBT's S-1 is the key. Shouldn't be far off now. Two, we had just gotten our dividend paid, then the pop comes, traders and recent underwater longs have been getting out since the China deal news. All those new shares in the float had to get swallowed. Our overall timing is awful even though CV is what gave us the opportunity in the first place. An unexpected opportunity.
Read the line I highlighted in CYDY's press release today about injecting Covid-19 patient's with leronlimab.
U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s Leronlimab
Download as PDFMarch 19, 2020 6:00am EDT
A leading academic medical center has administered the test medication, leronlimab, in two of their sickest COVID-19 patients. Neither patient has had any serious adverse reactions to leronlimab since it was administered. We are hopeful leronlimab will provide help to severely ill COVID-19 patients.
VANCOUVER, Washington, March 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that two coronavirus patients were treated with the Company’s investigational new drug, leronlimab. The treatment was administered at a leading medical center in the New York City area under an emergency Investigational New Drug (IND) recently granted by the U.S. Food and Drug Administration (FDA). Leronlimab is intended to serve as a therapy for patients who experience respiratory illness as a result of contracting the Coronavirus Disease 2019 (COVID-19). The treatment of these patients was not under the Company’s proposed randomized controlled Phase 2 clinical trial protocol recently submitted to the FDA. Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn, added, “Leronlimab binds to the CCR5 receptor inhibiting the migration of macrophages and the release on inflammatory cytokines including TNF and IL-6. This release of cytokines is what is commonly referred to as the 'cytokine storm' and is believed to cause profound damage in the lungs in some patients. In addition, leronlimab can block Regulatory T cells (Tregs), which can inhibit the innate immune response against pathogens, into areas of inflammation. These combined mechanisms of action may reduce the morbidity and mortality in moderate to severe cases of COVID-19, preventing the acute respiratory distress syndrome associated with this highly destructive and potentially fatal disease.”
Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said, “We are very pleased that we have a potential treatment option for patients affected by COVID-19 infection. To be very clear, leronlimab does not kill the novel coronavirus. It acts as a CCR5 antagonist by blocking pro-inflammatory cytokines, which prevents cytokine storm and thus could be useful in treatment of COVID-19. Leronlimab is administered as a once-a-week injection. It has a strong safety profile demonstrated in nine clinical trials with over 800 people and is available for urgent treatment. If results are promising, we have leronlimab available for immediate use and the ability to scale production. We are open and willing to work with government agencies and pharmaceutical partnerships to assist in serving those in dire need of a treatment option for this devastating disease. We appreciate the FDA’s prompt response and are working in full support of the treating medical team.”
My point is, we are not the only one's starving for the world's attention guys. Worse than that CYDY uses the selling of shares and warrants to raise money thus diluting shareholders. They just did it again today, probably the fourth or fifth time they have since I bought in. Once was for less than 30 cents. That is painful to suffer through. Joe has done everything he can do to avoid having us endure that kind of dilution. He could have done it and we could have hundreds of millions shares in the float to work through before we see a positive return.
We have a more than solid leadership team. Even if Joe is a bit unorthodox in his individual communications and posts, you cannot deny he is well liked by many of his peers. They are still here after all this time and more coming on board because of his vision and the future potential. One cannot ignore what TT, Dr Patel and the new NGIO BOD have accomplished in their professional careers. It isn't all on Joe's shoulders. Why are all these folks on board? It isn't because of the current pay.
I think the rest of March and April will be interesting. Come on SEC, let's get Generex's S-1 approved!
Stay well...
(5)
(0)